# Clearside Biomedical (CLSD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CLSD
## Company Profile
- Ticker: CLSD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
Clearside Biomedical is a drug-delivery and ophthalmology company focused on delivering therapies directly to the back of the eye. Its platform is built around improving how eye treatments reach retinal tissue.
## Why The Stock Is Moving

Current closing-price context is not available for CLSD.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Clearside sits in specialty ophthalmology biotechnology.

## Business Model

The company depends on delivery technology, clinical progress, and the ability to create an eye-care franchise.

## Landscape Position

Clearside is a niche ophthalmology catalyst name whose stock is tied to clinical and delivery milestones.

## Future Catalysts

- Clearside’s catalysts are suprachoroidal delivery programs and any ophthalmology update that keeps the platform relevant. The market will care about whether the delivery method still differentiates the story.

## Recent News
- 2025-11-24 12:05 EST — [Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process](https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process) — Source: Clearside Biomedical
- 2025-08-26 12:05 EST — [Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-on-suprachoroidal-delivery-to-be-featured-at-the-25th-euretina-congress) — Source: Clearside Biomedical
- 2025-07-23 11:05 EST — [Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-approval-of-xiperer-suprachoroidal-treatment-for-uveitic-macular-edema-in-canada) — Source: Clearside Biomedical
- 2025-07-17 11:05 EST — [Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-scsr-delivery-platform-and-promising-ophthalmology-pipeline) — Source: Clearside Biomedical
- 2025-06-17 11:05 EST — [Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-to-be-featured-at-the-clinical-trials-at-the-summit-meeting) — Source: Clearside Biomedical